Navigation Links
US Oncology Appoints Glen Laschober EVP & Chief Operating Officer
Date:12/5/2007

HOUSTON, Dec. 5 /PRNewswire/ -- US Oncology, the nation's leading oncology services company, today named Glen Laschober as the company's new executive vice president and chief operating officer. The appointment becomes effective on January 2, 2008.

"Glen's Fortune 500 operating experience, combined with his work in large diversified healthcare organizations, greatly strengthens our existing operating team," said Bruce Broussard, president of US Oncology. "His proven success in working with physicians and healthcare professionals, in areas such as care management programs, process efficiency and leadership development, will accelerate the implementation of our company's initiatives, such as Practice and Quality Efficiency (PQE) and Comprehensive Disease Management, including Cancer Care Pathways."

"I am very pleased to join US Oncology. The company has many exciting opportunities to continue its strong growth as a leading oncology services provider," said Laschober. "Just as importantly, their mission is very compelling to me. Cancer is a devastating disease that touches the lives of a large number of people. I welcome the opportunity to help improve the quality of life for cancer patients and their families."

Laschober brings to US Oncology more than 30 years of healthcare operations experience. Most recently, he served as the chief operating officer for Omnicare, a Fortune 500 healthcare company with revenues of $6.5 billion. He has also been an executive operating officer in several other highly successful organizations such as CVS, Provantage, and Caremark. He began his healthcare career in a variety of engineering and technology operations positions working with medical devices and pharmaceutical products at G.D. Searle, Inc, currently a division of Pfizer. He graduated from the University of Illinois with a B.S. in Engineering, and from the University of Chicago with an M.B.A. in Finance.

He will be based at the company's headquarters in Houston, Texas and will report to Broussard.

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. US Oncology to Report 2007 Third Quarter Earnings Results
7. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
10. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
11. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and ... woman’s life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a ... Charlotte, who credits the inspiration of the book to her sister, Denise, wishes to ...
(Date:1/23/2017)... ... January 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and ... who may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is ... $25 free. Or, spend $200 and get $50 free. , “A lot of people ...
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
(Date:1/21/2017)... ... 2017 , ... Seamild, the largest manufacturer of oats in China, is now ... founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, the ... it is a move to sow the seed of good karma. Buddhism spirit featuring ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... -- ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B Medical ... se sont mis d,accord sur le règlement mondial de ... 3B seront autorisés à vendre leurs produits existants en ... effectuera le paiement de la décision en une seule ... entre les deux parties. Le règlement n,inclut pas l,admission ...
(Date:1/23/2017)... Jan 23, 2017 InDex Pharmaceuticals Holding AB ... the 12th congress of the European Crohn,s and Colitis Organisation (ECCO). ... a specific focus on inflammatory bowel disease (IBD). The congress is ... 2017. ... are pleased to again having been selected to present data at ...
Breaking Medicine Technology: